FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022321186> ?p ?o ?g. }

• W2022321186 abstract "To determine whether strategies can be devised for the assessment and treatment of glucocorticoid-induced osteoporosis (GIO).Electronic databases were searched up to October 2002.A systematic review of interventions was undertaken of all randomised controlled trials in which fracture was measured as an outcome. Effectiveness was compared with effectiveness in postmenopausal osteoporosis. The risk of osteoporotic fractures at any given T-score for bone mineral density (BMD) was determined from published meta-analyses of the relationship between BMD and fracture risk. The risk of an osteoporotic fracture in the presence of a prior osteoporotic fracture was computed from a published meta-analysis of the relationship between the prior occurrence of fracture of each type and the risk of a future fracture of each type. The additional risk due to exposure to glucocorticoids was determined by meta-analysis of prospectively studied population-based cohorts. The consequences of fracture on mortality were assessed for each fracture type. Costs and utilities were determined for osteoporosis in the UK by updating systematic reviews of the literature. A model was prepared that comprised an individual patient-based approach that simulated whether or not events occurred in each subsequent year for each patient. Effectiveness was populated from a systematic review of interventions in GIO and postmenopausal osteoporosis. Treatments were given for 5 years using a 5-year offset time (in this context, offset time is the duration for which an effect on fracture persists after the treatment stops). The analytic framework was set at 10 years. Because of the many uncertainties, extensive sensitivity analysis was undertaken.Evidence of anti-fracture efficacy was confined to a minority of agents used in the management of GIO. Only risedronate (a bisphosphonate) and calcidiol (vitamin D) were shown to have significant effects on vertebral fracture risk, but neither had significant effects on non-vertebral fracture risk. In further meta-analyses, the effects of bisphosphonates in GIO were compared with effects combining all available data for bisphosphonates in GIO and in postmenopausal osteoporosis. Since calcidiol is not licensed for use in the UK, cost-effectiveness analysis was confined to risedronate and to a pooled bisphosphonate effect. Analysis of cost-effectiveness of risedronate using the empirical data in GIO showed better cost-effectiveness with increasing age, but at no age did cost-effectiveness ratios fall below the threshold value of 30,000 pounds per quality-adjusted life-year gained. When account was taken of BMD, cost-effectiveness was confined to less than 10% of patients with very low T-scores for BMD. Assuming that bisphosphonate efficacy on fracture risk was comparable to that observed with bisphosphonates in postmenopausal osteoporosis, cost-effectiveness was shown in patients with a prior fracture. In patients with no prior fracture, cost-effectiveness was observed in individuals aged 75 years or more. In younger patients without a prior fracture, cost-effective scenarios were found contingent upon a T-score for BMD that was 2.0 SD or less.Cost-effective scenarios for risedronate in the management of GIO were identified, but only at the extremes of age and T-score, such that less than 10% of patients aged 50 years or more would be eligible for treatment. Greater cost-effectiveness was observed assuming that the effects of bisphosphonate in GIO were similar to those observed in postmenopausal osteoporosis, an assumption tested by meta-analysis. An assessment algorithm is proposed based on age, the presence of a prior fragility fracture and BMD tests in individuals aged 50 years or more with no fracture. The conclusions derived are conservative, mainly because of the assumptions that were made in the absence of sufficient data. Thus, conclusions that treatment scenarios are cost-effective are reasonably secure. By contrast, scenarios shown not to be cost-effective are less secure. As information in these areas becomes available, the implications for cost-effectiveness of interventions should be reappraised. Health economic assessment based on probability of fracture is an important area for further research. Other areas for further research arise from gaps in empirical knowledge on utilities and side-effects that are amenable to primary research. Further secondary research is recommended to evaluate more closely the impact of all vertebral fractures (rather than clinically overt vertebral fractures) on cost-effectiveness and methods of monitoring treatment." @default.
• W2022321186 created "2016-06-24" @default.
• W2022321186 creator A5024756058 @default.
• W2022321186 creator A5037004738 @default.
• W2022321186 creator A5044747870 @default.
• W2022321186 creator A5052330918 @default.
• W2022321186 creator A5075838019 @default.
• W2022321186 date "2007-03-01" @default.
• W2022321186 modified "2023-10-17" @default.
• W2022321186 title "Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis" @default.
• W2022321186 cites W110053699 @default.
• W2022321186 cites W123345555 @default.
• W2022321186 cites W1482721567 @default.
• W2022321186 cites W1486889235 @default.
• W2022321186 cites W1492612191 @default.
• W2022321186 cites W1525845107 @default.
• W2022321186 cites W1526826623 @default.
• W2022321186 cites W1551414180 @default.
• W2022321186 cites W1564323166 @default.
• W2022321186 cites W1573139468 @default.
• W2022321186 cites W1573883118 @default.
• W2022321186 cites W1576813196 @default.
• W2022321186 cites W1580781263 @default.
• W2022321186 cites W168150526 @default.
• W2022321186 cites W1735506280 @default.
• W2022321186 cites W1786860485 @default.
• W2022321186 cites W184587151 @default.
• W2022321186 cites W190001218 @default.
• W2022321186 cites W1900105093 @default.
• W2022321186 cites W193557079 @default.
• W2022321186 cites W1963783263 @default.
• W2022321186 cites W1963785335 @default.
• W2022321186 cites W1964001203 @default.
• W2022321186 cites W1964700122 @default.
• W2022321186 cites W1964907392 @default.
• W2022321186 cites W1965209482 @default.
• W2022321186 cites W1965633872 @default.
• W2022321186 cites W1966391931 @default.
• W2022321186 cites W1966623098 @default.
• W2022321186 cites W1966813919 @default.
• W2022321186 cites W1967642140 @default.
• W2022321186 cites W1967700838 @default.
• W2022321186 cites W1968418396 @default.
• W2022321186 cites W1968719103 @default.
• W2022321186 cites W1969054391 @default.
• W2022321186 cites W1969383313 @default.
• W2022321186 cites W1969564030 @default.
• W2022321186 cites W1970182232 @default.
• W2022321186 cites W1970400080 @default.
• W2022321186 cites W1970501743 @default.
• W2022321186 cites W1972318181 @default.
• W2022321186 cites W1972567404 @default.
• W2022321186 cites W1973591042 @default.
• W2022321186 cites W1974047476 @default.
• W2022321186 cites W1974157576 @default.
• W2022321186 cites W1974249370 @default.
• W2022321186 cites W1974464819 @default.
• W2022321186 cites W1974963363 @default.
• W2022321186 cites W1975230482 @default.
• W2022321186 cites W1975492662 @default.
• W2022321186 cites W1977262832 @default.
• W2022321186 cites W1977852268 @default.
• W2022321186 cites W1979035516 @default.
• W2022321186 cites W1979066880 @default.
• W2022321186 cites W1979193732 @default.
• W2022321186 cites W1979270481 @default.
• W2022321186 cites W1979368971 @default.
• W2022321186 cites W1980550139 @default.
• W2022321186 cites W1980674181 @default.
• W2022321186 cites W1982043664 @default.
• W2022321186 cites W1982707245 @default.
• W2022321186 cites W1983391342 @default.
• W2022321186 cites W1985500418 @default.
• W2022321186 cites W1985504487 @default.
• W2022321186 cites W1986621723 @default.
• W2022321186 cites W1986855432 @default.
• W2022321186 cites W1987809980 @default.
• W2022321186 cites W198876260 @default.
• W2022321186 cites W1990808425 @default.
• W2022321186 cites W1993542424 @default.
• W2022321186 cites W1996336099 @default.
• W2022321186 cites W1996673559 @default.
• W2022321186 cites W1996926816 @default.
• W2022321186 cites W1997134248 @default.
• W2022321186 cites W1997552635 @default.
• W2022321186 cites W1998169299 @default.
• W2022321186 cites W1999401950 @default.
• W2022321186 cites W1999466669 @default.
• W2022321186 cites W2000126649 @default.
• W2022321186 cites W2000263013 @default.
• W2022321186 cites W2000950923 @default.
• W2022321186 cites W2001066372 @default.
• W2022321186 cites W2001121508 @default.
• W2022321186 cites W2001388768 @default.
• W2022321186 cites W2002245044 @default.
• W2022321186 cites W2002315967 @default.
• W2022321186 cites W2002332655 @default.
• W2022321186 cites W2005298224 @default.
• W2022321186 cites W2005326563 @default.
• W2022321186 cites W2005614069 @default.

• next